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Introduction
According to cancer statistics of 2013, prostate cancer 
is still at the top of estimated new cancer cases and it is the 
second cause of death due to cancer(Arshad and Ahmad, 
2013; Siegel et al., 2013). Therefore, early diagnosis 
and treatment is utmost importance in the management 
of prostate cancer. In our practice, PSA analysis in the 
elderly depends mainly on either physical examination 
and/or lower urinary tract symptom driven suggestion, 
or patient’s own will as a continuation of yearly PSA 
screening. However, this practice brings out another 
question: to perform or not to perform biopsy for high 
PSA levels in the elderly, as well any cut off age or cut off 
PSA level for biopsy, keeping medico-legal issues in mind.
 In this retrospective study, we aimed to determine 
results of high PSA or abnormal digital rectal examination 
driven prostate biopsies performed in our department in 
men aged 75 or more and to show the characteristics of 
pathology results and demographics of the patients.
Materials and Methods
In three common university based research hospitals, 
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the hospital records of patients who had high PSA or 
abnormal digital rectal examination driven prostate biopsy 
between dates of January 2010 and June 2013 have been 
reviewed retrospectively. Records providing pathology 
results and full medical history of patients who are aged 
75 and over at the date of biopsy were included in data 
analyses.
The patients were also compared according to their 
age decades for their pathology results and treatments. 
For statistical analyses, SPSS statistics version 17 was 
used. For group comparisons, chi-square test was used. 
Tests with p-value less than < 0,05 was set as statistically 
significant.
Results 
A total of 103 patients’ records have been included 
in the data analyses. The mean age was 79.42 ±3.4 
years. More than half of the patients (55.1%) were in the 
seventh decade and the rest were in the eighth decade . 
Median PSA value was 15.0 (range 2.1- 4500) ng/ml. In 
most of the biopsies (67%), PSA levels were lower than 
20 ng/ml. In almost half of the patients (48%), digital 
rectal examination was abnormal. LUTS was present 
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in 62.1% of the patients. In 68.9% of the patients, there 
were at least one or more associated co-morbid diseases. 
Of these patients, 11% had Diabetes Mellitus, 32% had 
hypertension, 26% had coronary artery disease, 15% had 
neurological disease, 3% had chronic renal failure, and 
26% had other kinds of co-morbid diseases (Figure 1).
One third of the patients were taking anti-coagulant 
medications. The pathology results of the prostate biopsies 
were prostate adenocarcinoma in 68%, ASAP in 1%, and 
BPH in the rest of the patients (Figure 2).
Gleason scores were 7 or higher in 73%, and 8 or higher 
in 37% of the patients with prostate cancer. Four of the 
70 (6%) patients had bone metastases. Ones with benign 
pathology results were followed with PSA measurements. 
Most of the patients with prostate adenocarcinoma (%79) 
were applied castration. In these cases, medical castration 
was mostly preferred (82%). When compared in terms 
of modality of hormone ablation therapy between age 
groups, similar rates of surgical and medical castration 
were present in both eighth and ninth decades (Figure 3). 
In addition, LUTS was more frequent in ones with PSA 
levels lower than 20 ng/ml (71% vs. 44% with p < 0.01).
Discussion
Prostate cancer, being a common cancer in men and 
second cause of death due to cancer, necessitates early 
diagnosis and treatment (Arshad and Ahmad, 2013; Siegel 
et al.). Although both major authorities, namely EAU 
and AUA, offered clinical guidelines for diagnosis, yet 
they are somewhat unclear on the subject of treatment 
and follow up of prostate cancer in elderly (Carter et al., 
2013; Heidenreich et al., 2014). As well the US Preventive 
Services Task Force (USPSTF) has recommended 
against routine PSA screening for prostate cancer and 
claimed upper limit of age as 75 in an earlier version 
(Moyer, 2012). However, this lack of clear guidance on 
this point is well reflected by the treatment practices of 
urologists which show a great variance (Lipinski et al., 
2013; Situmorang et al., 2013; Verim et al., 2013). In our 
practice, PSA analysis in the elderly depends mainly on 
either physical examination and/or lower urinary tract 
symptom driven suggestion, or patient’s own will as a 
continuum of yearly PSA screening. Likewise, a recent 
analysis of Medicare Health system related to prostate 
cancer diagnosis and treatment showed that PSA screening 
rate was 32,6% in men aged between 66-74 years and 
28,7% in men aged between 75-84, where half of screened 
population was over 75 years (Ma et al.). Additionally, in 
the cost effectiveness analyses, an inverse relation between 
age and screening cost was found (Ma et al.).
On the contrary, a recent meta-analysis on PSA 
screening regardless of age was found to be related to 
overdiagnosis and overtreatment (Ilic et al.). However, 
rather than screening, ad hoc PSA testing has been 
suggested to be related to low levels of over-treating 
(Samaratunga et al.).
In a report, patients aged 70 or older were reported 
to have more than a three-fold increased risk of Gleason 
score of 7 or greater cancer (Hanson et al., 2007). This 
finding is supported with our study, with Gleason scores 
≥ 7 in 85% and ≥ 8 in 64% of the patients. In a series 
of 1446 needle biopsies of the prostate in men aged 75 
or older, where the mean serum PSA level for patients 
biopsied was 10.4 mug/L, prostate cancer detection rate 
was 53%, and of these 78% was defined as clinically 
significant cancer (Mistry et al., 2009). This increased 
risk of tumour aggressiveness is also well reflected in 
the radical prostatectomy series where 90% men aged 
>70-year-old showed approximately Gleason score ≥7 
in prostatectomy specimen, and significant failure rate 
compared to the matched younger patients (Ko et al., 
2013). However, in another retrospective study, which 
analyzed 386 operated men aged between 70-81, it was 
concluded that when appropriate patients is chosen for 
radical prostatectomy, the prostate cancer-specific survival 
rate was 97.6%, 94.0%, and 90.2% at 5, 10 and 15 years 
respectively after RP (Pierorazio et al.). 
Therefore, whether definitive treatment is appropriate 
or not, all elderly who is definitively under risk of high 
grade prostate cancer seem to deserve diagnostic work up 
when suspected, including prostate biopsy. 
Figure 1. Comorbidities
Figure 2. Biopsy Results
Figure 3. Types of Treatment
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